EARNIX
11.1.2023 18:37:39 CET | Business Wire | Press release
Earnix, the market-leading provider of mission-critical cloud-based intelligent real-time, dynamic pricing and rating solutions for insurers and banks, today announced it is appointing insurance and fintech industry veteran, Robin Gilthorpe, as its new Chief Executive Officer effective February 1, 2023. Mr. Gilthorpe will be taking over the helm from Mr. Udi Ziv, who served as the company’s CEO over the past six years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005784/en/
Robin Gilthorpe, CEO, Earnix (Photo: Business Wire)
Robin Gilthorpe, a veteran of the finance and insurance industries, brings to the role over 25 years of experience as a successful business leader. Throughout his career, Mr. Gilthorpe has held numerous executive leadership roles at leading technology and insurance companies such as TIBCO, Vertexone, Watersmart Software, DataSynapse and ESW Capital. In his most recent role at Insurtech innovator Salty, Gilthorpe served as Chief Operating Officer, generating a nine-figure outcome in sale to CDK Global.
“I am thrilled to be joining Earnix at this crucial time in the global economy,” said Robin Gilthrope, incoming CEO at Earnix. “Financial services companies across the globe are seeking intelligent operations to ensure they can offer real-time, dynamic solutions, to better serve customers, enabling them to be more agile, nimble, attentive, and responsive. Today’s end-customer demands unparalleled experience, alongside highly personalized and customizable solutions. Earnix solutions serve as the go-to platform for financial services companies to address the growing demands of the world’s leading financial and insurance companies.”
His hiring comes on the heels of a period of growth for Earnix led by exiting CEO Udi Ziv. Mr. Ziv joined Earnix in 2017 and in his six years with the firm has led the company to consistent growth, achieving Unicorn status and important strategic alliances including forging the recently announced strategic partnership with Guidewire as well as engagements with USAA, MAPFRE, IAG, Liberty Mutual, US Bank, Lloyd’s Banking Group, and many more. Mr. Ziv built a strong team of leaders positioned to drive the company’s continued growth. Udi will serve as one of the industry experts on the Earnix Board of directors.
“We are proud to welcome Robin to the Earnix family, and believe that his experience in building global, international companies, alongside the growing demand for Earnix’s suite of real-time, dynamic, composable Intelligent InsurOps solutions, will lead Earnix to significant growth over the next few years, and bring Earnix to international market leadership, with its real-time operation platform for the largest insurance companies and banking institutions,” said Erel Margalit, JVP Founder & Executive Chairman and Earnix's Chairman of the Board, “We want to thank Udi for his important role, over the last few years. With its growing presence in North America, Europe, Asia Pacific, and Israel, Earnix will continue to strive to become the category leader, in the real-time AI usage-based insurance and banking industry.”
“I’ve very much enjoyed my tenure at Earnix, leading the company to consistent year over year growth, and strongly believe in our people and products as a change agent for financial services companies,” Udi Ziv, exiting CEO, Earnix, said. “I believe now is the time to move on to my next endeavor as the company prepares for its next stage of international expansion. I firmly believe I am leaving the company in very capable hands with Robin and expect that the company will continue the rapid global growth Earnix has experienced in the last few years.”
About Earnix
Earnix is the premier provider of mission-critical composable and cloud-based intelligent solutions across pricing, rating, underwriting, product personalization and telematics. These fully integrated solutions provide ultra-fast ROI and are designed to transform how global insurers and banks are run by unlocking value across all facets of the business. It has been innovating for Insurers and Banks since 2001 with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel. Earnix shareholders include JVP, Insight Partners, IGP, and Vintage Investment Partners.
For more information please visit: earnix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005784/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
